Alimera Sciences

Alpharetta, United States Founded: 2003 • Age: 23 yrs Acquired By ANI Pharmaceuticals
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized.
Request Access

About Alimera Sciences

Alimera Sciences is a company based in Alpharetta (United States) founded in 2003 was acquired by ANI Pharmaceuticals in July 2024. It operates as a Reseller / Distribution. Alimera Sciences has raised $66.8 million across 9 funding rounds from investors including ANI Pharmaceuticals, SLR Investment Corp and Lincoln Park Capital. The company has 79 employees as of December 31, 2022. Alimera Sciences offers products and services including Ophthalmic Products. Alimera Sciences operates in a competitive market with competitors including Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others.

  • Headquarter Alpharetta, United States
  • Employees 79 as on 31 Dec, 2022
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Alimera Sciences Europe Ltd
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $80.75 M
    49
    as on Dec 31, 2023
  • Net Profit
    $-20.13 M
    -11
    as on Dec 31, 2023
  • EBITDA
    $6.82 M
    176
    as on Dec 31, 2023
  • Total Equity Funding
    $66.8 M (USD)

    in 9 rounds

  • Latest Funding Round
    $81 M (USD), Post-IPO

    May 31, 2023

  • Investors
  • Employee Count
    79

    as on Dec 31, 2022

  • Acquired by
    ANI Pharmaceuticals

    (Jul 17, 2024)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Alimera Sciences

Alimera Sciences offers a comprehensive portfolio of products and services, including Ophthalmic Products. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Products for eye conditions are developed and distributed.

People of Alimera Sciences
Headcount 50-200
Employee Profiles 41
Employee Profiles
People
Russell Skibsted
CFO & SVP
People
Janine Ainslie Harris
Global Creative And Communications Lead
People
Cheryl O'Keeffe
Field Sales Trainer
People
Emma Head
Human Resources Business Partner, Europe

Unlock access to complete

Funding Insights of Alimera Sciences

Alimera Sciences has successfully raised a total of $66.8M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $81 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 9
  • Last Round Post-IPO — $81.0M
  • First Round

    (30 Nov 2005)

  • Investors Count 7
Date Amount Transaction Name Valuation Lead Investors Investors
May, 2023 Amount Post-IPO - Alimera Sciences Valuation

investors

Oct, 2019 Amount Post-IPO - Alimera Sciences Valuation

investors

Jan, 2018 Amount Debt – Conventional - Alimera Sciences Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Alimera Sciences

Alimera Sciences has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include ANI Pharmaceuticals, SLR Investment Corp and Lincoln Park Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Private equity investments are directed toward North American opportunities.
Founded Year Domain Location
Debt and equity investments are offered by the firm.
Founded Year Domain Location
US focused venture capital firm
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Alimera Sciences

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Alimera Sciences

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Alimera Sciences Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Alimera Sciences

Alimera Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of therapeutic solutions for the treatment of diabetes
domain founded_year HQ Location
Developer of antibodies to treat complement-mediated neurodegenerative diseases
domain founded_year HQ Location
Drug candidates for immune-mediated diseases are developed by Aldeyra.
domain founded_year HQ Location
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
domain founded_year HQ Location
Mobile SDK developed for app engagement and monetization strategies.
domain founded_year HQ Location
Gene therapies for ocular and neurodegenerative diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Alimera Sciences

Frequently Asked Questions about Alimera Sciences

When was Alimera Sciences founded?

Alimera Sciences was founded in 2003 and raised its 1st funding round 2 years after it was founded.

Where is Alimera Sciences located?

Alimera Sciences is headquartered in Alpharetta, United States. It is registered at Alpharetta, Georgia, United States.

Is Alimera Sciences a funded company?

Alimera Sciences is a funded company, having raised a total of $66.8M across 9 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $40M, raised on Nov 30, 2005.

How many employees does Alimera Sciences have?

As of Dec 31, 2022, the latest employee count at Alimera Sciences is 79.

What is the annual revenue of Alimera Sciences?

Annual revenue of Alimera Sciences is $80.75M as on Dec 31, 2023.

What does Alimera Sciences do?

Alimera Sciences is involved in the distribution of ophthalmic pharmaceutical products across Europe, the Middle East, and Africa. The company collaborates with a network of distribution partners to provide solutions for eye-related conditions. Operations are focused on ensuring access to specialized treatments in various countries within these regions.

Who are the top competitors of Alimera Sciences?

Alimera Sciences's top competitors include Annexon, MeiraGTx and Aldeyra.

What products or services does Alimera Sciences offer?

Alimera Sciences offers Ophthalmic Products.

Who are Alimera Sciences's investors?

Alimera Sciences has 8 investors. Key investors include ANI Pharmaceuticals, SLR Investment Corp, Lincoln Park Capital, Polaris Partners, and Intersouth Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available